Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Abstract Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines was reported in studies in several countries, data is limited from Asian countries, especially against the Delta (B.1.617.2) variant.Methods We conducted a multicenter test-negative case-control study in patients aged ≥16 visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from July 1 to September 30, 2021, when the Delta variant was dominant (≥90% of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16 to 64 was also assessed.Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving two doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8–93.9) among patients aged 16 to 64 and 90.3% (95% CI, 73.6–96.4) among patients aged ≥65. Among patients aged 16 to 64, vaccine effectiveness within one to three months after full vaccination was 91.8% (95% CI, 80.3–96.6), and was 86.4% (95% CI, 56.9–95.7) within four to six months.Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July 1 to September 30, 2021, when the Delta variant was dominant nationwide..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 25. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maeda, Haruka [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2022.01.17.22269394 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035051590 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035051590 | ||
| 003 | DE-627 | ||
| 005 | 20230429074919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220124s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.01.17.22269394 |2 doi | |
| 035 | |a (DE-627)XBI035051590 | ||
| 035 | |a (biorXiv)10.1101/2022.01.17.22269394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Maeda, Haruka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines was reported in studies in several countries, data is limited from Asian countries, especially against the Delta (B.1.617.2) variant.Methods We conducted a multicenter test-negative case-control study in patients aged ≥16 visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from July 1 to September 30, 2021, when the Delta variant was dominant (≥90% of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16 to 64 was also assessed.Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving two doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8–93.9) among patients aged 16 to 64 and 90.3% (95% CI, 73.6–96.4) among patients aged ≥65. Among patients aged 16 to 64, vaccine effectiveness within one to three months after full vaccination was 91.8% (95% CI, 80.3–96.6), and was 86.4% (95% CI, 56.9–95.7) within four to six months.Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July 1 to September 30, 2021, when the Delta variant was dominant nationwide. | ||
| 700 | 1 | |a Saito, Nobuo |e verfasserin |4 aut | |
| 700 | 1 | |a Igarashi, Ataru |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Suami, Kazuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yagiuchi, Ai |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Yuya |e verfasserin |4 aut | |
| 700 | 1 | |a Komino, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Morikawa, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Motohashi, Iori |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazawa, Rei |e verfasserin |4 aut | |
| 700 | 1 | |a Moriyama, Tetsu |e verfasserin |4 aut | |
| 700 | 1 | |a Kamura, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Mayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwamitsu, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Tomoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sando, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ohara, Yasuji |e verfasserin |4 aut | |
| 700 | 1 | |a Teshigawara, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Motoi |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Konosuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 25. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:05 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/cid/ciac292 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.01.17.22269394 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 05 | ||
| 953 | |2 045F |a 570 | ||